A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07357675

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
EBI Anti Sepsis BV (from the registry)
Registry
  • NCT NCT07357675
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Netherlands, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07357675. Randomized; triple masking; primary purpose treatment. Start 2026-10-29 (actual); primary completion 2027-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
Acronym
EasyBoost
Condition
Coronary Artery Bypass Graft Surgery(CABG (coronary artery bypass grafting))
Intervention (Drug)
EA-230 90mg/kg/hour
Intervention (Drug)
Placebo
Lead sponsor
EBI Anti Sepsis BV (class: industry)
Collaborator
CR2O B.V. (class: not stated)

Record details

Record id
cardio:ct-nct07357675
Content hash
2791a207eda0ca40f1b106d525fd6c9756deb9315a1dc7f4b13de8eda68ec60c